Open Access Full Text Article

ORIGINAL RESEARCH

Population Genetic Difference of Pharmacogenomic VIP Variants in the Tibetan Population

Chunjuan He[1]
Linna Peng[1]
Shishi Xing[1]
Dandan Li[1]
Li Wang [ID][1]
Tianbo Jin [ID][1,2]

[1]Key Laboratory of Molecular Mechanism and Intervention Research for Plateau Diseases of Tibet Autonomous Region, School of Medicine, Xizang Minzu University, Xianyang, Shaanxi, 712082, People's Republic of China; [2]Key Laboratory for Basic Life Science Research of Tibet Autonomous Region, Xizang Minzu University, Xianyang, Shaanxi, 712082, People's Republic of China

Correspondence: Tianbo Jin
Key Laboratory of Molecular Mechanism and Intervention Research for Plateau Diseases of Tibet Autonomous Region, School of Medicine, Xizang Minzu University, #6, Wenhui East Road, Xianyang, 712082, Shaanxi, People's Republic of China
Tel/Fax +86-29-88895902
Email jintianbo@gmail.com

Background: Genetic variation influences drug reaction or adverse prognosis. The purpose of this research was to genotype very important pharmacogenetic (VIP) variants in the Tibetan population.
Methods and Materials: Blood samples from 200 Tibetans were randomly collected and 59 VIP variants were genotyped, and then compared our data to 26 other populations in the 1000 project to further analyze and identify significant difference.
Results: The results showed that on comparing with most of the 26 populations from the 1000 project, rs4291 (*ACE*), rs1051296 (*SLC19A1*) and rs1065852 (*CYP2D6*) significantly differed in the Tibetan population. Furthermore, three significant loci were related to drug response. In addition, the allele frequency of Tibetans least differed from that of East Asian populations, and most differed from that of Americans.
Conclusion: Three significant loci of variation *ACE* rs4291, *SLC19A1* rs1051296 and *CYP2D6* rs1065852 were associated with drug response. This result will contribute to improving the information of the Tibetan in the pharmacogenomics database, and providing a theoretical basis for clinical individualised drug use in Tibetans.
Keywords: the Tibetan population, pharmacogenomics, VIP variants

Introduction

A major challenge in current drug clinical practice, drug development and drug regulation is the huge difference in drug treatment[1] which is reasoned to the individual differences for the same drug.[2] Single nucleotide polymorphism (SNP) is an important determinant of individual differences in drug therapy. Pharmacogenomics mainly involves knowledge of pharmacokinetic, pharmacodynamic and focuses on the inheritance of individual variation in the course of drug treatment, clarifies the influence of genomic variation on drug distribution and function, and provides guidance for individualised precise medical treatment[3,4] so on. The Pharmacogenomics Knowledge Base (PharmGKB: http://www.pharmgkb.org) is a useful resource that aims to explain the gene-drug-disease relationship. In recent years, pharmacogenomics research has largely focused on genetic variations that may be related to drug response or metabolism.[5] These variations–very important genetic (VIP) variants are mainly concentrated in the pharmacogenomics database. They assessed the relationship between the VIP variants and specific drugs, and provide individuals with appropriate drugs at proper doses.[6]

There are many differences in genetic heterogeneity and genetic polymorphism among different ethnic groups.[7] An important research hotspot in pharmacogenomics

1027

is to compare the efficacy of drugs among different races. Tibetan is one of the largest of the 56 ethnic Chinese nation, with a long history. Most Tibetans reside in the Tibet Autonomous Region on the Qinghai-Tibet Plateau, and some people also live in Qinghai, Gansu, Sichuan, Yunnan and other regions of China. The Tibetans have gradually formed unique ethnic custom, lifestyles and eating habits based on the climate and altitude of their residing areas. A study of the genomic variants in the Tibetan population showed that most of the Tibetan gene pool may be differ from the gene pool of the Han people.[8]

This study aimed to assess the genotype frequencies of 59 VIP variants between Tibetans and the other 26 ethnicities from the 1000 genome project. The results will contribute to improving the information of the Tibetan pharmacogenomics database, and providing a theoretical basis for drug management in Tibetans.

Materials and Methods
Study Participants

200 unrelated Tibetans were recruited from the Tibet Autonomous Region. According to the paternal lineage of at least past three generations, all candidates were confirmed to be Tibetan. Based on the results of physical examination, people with chronic diseases were excluded. The protocol of this study was known to all participants and they have signed informed consent. According to the ethics committee of Xizang Minzu University (2019-12), all participants provided blood samples. The procedures met the agency's ethical standards and the 1964 Helsinki Declaration and its subsequent amendments or similar ethical standards.

Variant Selection, DNA Extraction and Genotyping

The 59 VIP variants were selected from the PharmGKB database (http://www.pharmgkb.org). The genomic DNA of participants was extracted according to the extraction method of the blood DNA extraction kit (GoldMag Ltd. Xi'an, China), and then its DNA purity and concentration were inspected. Multiplexed SNP MassEXTEND assays were designed by the Agena MassARRAY Assay Design 3.0 software, and the Agena MassARRAY RS1000 was used to genotype the 59 VIP variants.[9] Data arrangement and analysis was performed by Agena Typer 4.0 software.[10,11]

Statistical Analyses

To determine whether the genotype frequencies of variants were in Hardy-Weinberg equilibrium, we used Microsoft Excel and SPSS 22.0 (SPSS, Chicago, IL) for statistical analysis. The genotype frequencies of 59 variants in the Tibetan population were separately compared with those of the other super-populations downloaded from the 1000 genomes project (http://www.internationalgenome.org/), including ①African: the African Caribbeans in Barbados (ACB); the African Ancestry in Southwest USA (ASW); Esan in Nigeria (ESN); Gambian in Western Divisions, The Gambia (GWD); the Luhya in Webuye, Kenya (LWK); the Mende in Sierra Leone (MSL); the Yoruba in Ibadan, Nigeria (YRI); ②American: the Colombian in Medellin, Colombia (CLM); the Mexican Ancestry in Los Angeles, Colombia (MXL); the Peruvian in Lima, Peru (Peruvian in Lima, Peru); the Puerto Rican in Puerto Rico (PUR); ③East Asian: the Chinese Dai in Xishuangbanna, China (CDX); the Han Chinese in Beijing, China (CHB0; the Southern Han Chinese, China (CHS); the Japanese in Tokyo, Japan (JPT); the Kinh in Ho Chi Minh City, Vietnam (KHV); ④European: the Utah residents with Northern and Western European ancestry (CEU); the Finnish in Finland (FIN); the British in England and Scotland (GBR); the Iberian populations in Spain (IBS); the Toscani in Italy (TSI); ⑤South Asian: the Bengali in Bangladesh (BEB); the Gujarati Indian in Houston, Texas (GIH); the Indian Telugu in the UK (ITU); the Punjabi in Lahore, Pakistan (PJL) and the Sri Lankan Tamil in the UK (STU).[12] Also, Bonferroni's multiple adjustments were used for significance assessment, and all p values were double-sided when $p < 0.05$ and $p < 0.05/(59 \times 27)$, the p value was considered to be statistically significant.[13]

Results

In the Table 1, we listed the basic characteristics of 59 VIP variants in 200 Tibetans and because of the nonspecific primers, 8 SNPs (rs1801252, rs1801160, rs2892949, rs12208357, rs1801279, rs10509681, rs1058930 and rs11572080) have been deleted. The selected SNP PCR primers were shown in Supplementary Table 1. The selected VIP gene information contained gene name, position, genotype frequency, the minor allele frequency and the functional consequence.

Based on the chi-squared test, as for the genotype frequencies of 59 variations, we made a comparison between Tibetans and other 26 nationalities (Supplementary Table 2).

Table 1 Basic Characteristics of the Selected VIP Variants from the PharmGKB Database and Genotype Frequencies in Tibetan Population

SNP	Genes	Chr	Position	Genotype			MAF	Functional Consequence
				AA	AB	BB		
rs11572325	CYP2J2	1	59,896,030	3	23	173	T=0.073	Intron_variant
rs10889160	CYP2J2	1	59,896,449	6	47	146	C=0.148	Intron_variant
rs890293	CYP2J2	1	59,926,822	0	98	94	A=0.255	Upstream_transcript_variant
rs1760217	DPYD	1	97,137,438	26	95	79	G=0.368	Genic_downstream_transcript_variant
rs1801159	DPYD	1	97,515,839	11	65	124	C=0.218	Coding_sequence_variant
rs1801158	DPYD	1	97,515,865	0	1	199	T=0.003	Coding_sequence_variant
rs1801265	DPYD	1	97,883,329	6	41	152	G=0.133	Non_coding_transcript_variant
rs5275	PTGS2	1	186,673,926	16	68	115	G=0.251	3_prime_UTR_variant
rs20417	PTGS2	1	186,681,189	0	7	193	G=0.018	Upstream_transcript_variant
rs12139527	CACNA1S	1	201,040,054	1	27	172	G=0.073	Missense_variant
rs13374149	CACNA1S	1	201,043,356	0	3	197	T=0.008	Missense_variant
rs3850625	CACNA1S	1	201,047,168	0	12	188	A=0.030	Coding_sequence_variant
rs12742169	CACNA1S	1	201,083,182	0	18	182	T=0.045	Missense_variant
rs12406479	CACNA1S	1	201,110,216	0	1	199	C=0.003	Missense_variant
rs2306238	RYR2	1	237,550,803	12	73	113	A=0.245	Intron_variant
rs2231142	ABCG2	4	88,131,171	0	29	171	T=0.073	Coding_sequence_variant
rs2231137	ABCG2	4	88,139,962	36	88	74	T=0.404	Coding_sequence_variant
rs698	ADH1C	4	99,339,632	5	38	156	C=0.121	Coding_sequence_variant
rs776746	CYP3A5	7	99,672,916	12	48	139	T=0.181	Intron_variant
rs2242480	CYP3A4	7	99,763,843	11	66	116	T=0.228	Intron_variant
rs1805123	KCNH2	7	150,948,446	0	200	0	G=0.500	Missense_variant
rs4646244	NAT2	8	18,390,208	6	70	123	A=0.206	Upstream_transcript_variant

(*Continued*)

Table 1 (Continued).

SNP	Genes	Chr	Position	Genotype			MAF	Functional Consequence
				AA	AB	BB		
rs4271002	NAT2	8	18,390,758	4	75	118	C=0.211	Upstream_transcript_variant
rs1041983	NAT2	8	18,400,285	39	84	74	T=0.411	Coding_sequence_variant
rs1801280	NAT2	8	18,400,344	0	12	188	C=0.030	Missense_variant
rs1799929	NAT2	8	18,400,484	0	11	189	T=0.028	Coding_sequence_variant
rs1799930	NAT2	8	18,400,593	13	120	66	A=0.367	Missense_variant
rs1208	NAT2	8	18,400,806	0	12	188	G=0.030	Missense_variant
rs1799931	NAT2	8	18,400,860	7	65	128	A=0.198	Missense_variant
rs1495741	NAT2	8	18,415,371	41	88	65	G=0.438	None
rs2115819	ALOX5	10	45,405,641	6	57	137	A=0.173	Intron_variant
rs12248560	CYP2C19	10	94,761,900	0	6	189	T=0.015	Upstream_transcript_variant
rs4244285	CYP2C19	10	94,781,859	8	78	107	A=0.244	Coding_sequence_variant
rs1057910	CYP2C9	10	94,981,296	1	23	176	C=0.063	Missense_variant
rs11572103	CYP2C8	10	95,058,349	0	12	188	A=0.030	Missense_variant
rs7909236	CYP2C8	10	95,069,673	5	58	136	T=0.171	Upstream_transcript_variant
rs17110453	CYP2C8	10	95,069,772	10	66	123	C=0.216	Upstream_transcript_variant
rs3813867	CYP2E1	10	133,526,101	0	26	174	C=0.065	Non_coding_transcript_variant
rs2031920	CYP2E1	10	133,526,341	2	52	142	T=0.143	Non_coding_transcript_variant
rs6413432	CYP2E1	10	133,535,040	0	1	199	A=0.003	Intron_variant
rs2070676	CYP2E1	10	133,537,633	10	58	132	G=0.195	Intron_variant
rs5219	KCNJ11	11	17,388,025	6	110	76	T=0.318	Missense_variant
rs1801028	DRD2	11	113,412,762	0	27	173	C=0.068	Missense_variant
rs2306283	SLCO1B1	12	21,176,804	10	87	100	A=0.272	Missense_variant
rs4516035	VDR	12	47,906,043	0	38	162	C=0.095	Upstream_transcript_variant

1030

DovePress

Pharmacogenomics and Personalized Medicine 2021:14

rs ID	Gene	Chr	Position	0	1	2	Frequency	Consequence
rs2472297	CYP1A2	15	74,735,539	0	1	199	T=0.003	None
rs762551	CYP1A2	15	74,749,576	33	80	84	C=0.371	Intron_variant
rs2472304	CYP1A2	15	74,751,897	1	21	178	A=0.058	Intron_variant
rs750155	SULT1A1	16	28,609,251	15	160	22	T=0.482	5_prime_UTR_variant
rs1800764	ACE	17	63,473,168	37	90	73	C=0.410	None
rs4291	ACE	17	63,476,833	0	199	1	T=0.498	Upstream_transcript_variant
rs4267385	ACE	17	63,506,395	5	55	138	T=0.164	None
rs2108622	CYP4F2	19	15,879,621	17	70	113	T=0.260	Missense_variant
rs3093105	CYP4F2	19	15,897,578	3	39	158	C=0.113	Missense_variant
rs8192726	CYP2A6	19	40,848,591	9	39	149	A=0.145	Intron_variant
rs1051298	SLC19A1	21	45,514,912	8	125	64	G=0.358	Intron_variant
rs1051296	SLC19A1	21	45,514,947	6	148	41	A=0.410	Intron_variant
rs1131596	SLC19A1	21	45,538,002	9	145	40	A=0.420	Missense_variant
rs1065852	CYP2D6	22	42,130,692	13	135	47	A=0.413	Intron_variant

Before adjustments, *ACE* rs4291, *SLC19A1* rs1051296 and *CYP2D6* rs1065852 significantly differed in the Tibetan population when compared with the other 26 nationalities. The *SULT1A1* rs750155, *SLC19A1* rs1051298 and *SLC19A1* rs1131596 in the Tibetan population were obviously different from those of the other nationalities. Bonferroni adjustments have been made ($p < 0.05/(59 \times 27)$). The results showed that *ACE* rs4291 and *CYP2D6* rs1065852 were significantly different in the Tibetan population when compared to the other 26 nationalities. Except for CHS, *SLC19A1* rs1051296 significantly differed in Tibetans when compared with the other 25 ethnic groups. Moreover, *SULT1A1* rs750155 and *SLC19A1* rs1131596 in the Tibetan population differed from those of the other 22 nationalities.

In addition, on the basis of Pharmgkb database (https://www.pharmgkb.org/), Table 2 showed the drug-related information of significant difference. The rs4291 carriers with different genotypes have different responses to drugs (sertraline, captopril, aspirin and amlodipinechlorthalidonelisinoprilj). Rs1065852 was found to be related to alpha-hydroxymetoprolol, citalopram escitalopram and iloperidone. As for rs1051298, compared to the allele A individuals, individuals with allele G were associated with increased progression free survival after bevacizumab and pemetrexed treatment. Compared with allele C, rs750155 T allele was not associated with ABT-751 pharmacokinetic parameters in cancer patients receiving ABT-751 treatment. And when comparing to the allele A, rs1131596 G allele was not correlated with the response to methotrexate in children with precursor cell lymphoblastic leukaemia lymphoma and patients with rheumatoid arthritis. The correlation between rs1051296 and clinical drugs has not been reported to date.

The MAF distribution map of SNPs *ACE* (rs4291 T allele), *SLC19A1* (rs1051296 A allele), *CYP2D6* (rs1065852 A allele), *SULT1A1* (rs750155 T allele), *SLC19A1* (rs1051298 G allele) and *SLC19A1* (rs1131596 A allele) were compared with significant differences between the Tibetans and the other super-populations. As shown in Supplementary Figure 1, the allele frequency of the Tibetans least differed from the East Asian populations, and most differed from Americans. Among them, the frequencies of rs4291-T and rs1065852-A were the highest in the East Asian population, whereas the frequency of rs1051296-A was the highest in the African population. The frequency of rs1051298-G, rs750155-T and rs1131596-A were the highest in the American population.

Discussion

In recent years, many studies have focused on the efficacy comparison of drug reactions among different races, which lays a foundation for clinical individualised drug use. This study identified 59 VIP loci in Tibetans and compared them with the other 26 different populations. Three significant loci of variation were inferred from the genotyping results, *ACE* rs4291, *SLC19A1* rs1051296 and *CYP2D6* rs1065852, which were associated with drug response.

Angiotensin-converting enzyme (ACE) encodes an enzyme involved in blood pressure regulation and electrolyte balance. It catalyses the conversion of angiotensin I into the physiologically active peptide angiotensin II. Angiotensin II promotes hypertension through vasoconstriction and salt and water retention, and is helpful for heart remodelling, inflammation, thrombosis and plaque rupture.[14] At present, ACE inhibitors are the first-line treatment for hypertension, which can favourably affect the remodelling of patients with myocardial infarction and heart failure, and reduce the incidence rate and mortality.[15] Therefore, ACE-encoded enzyme is the drug target.[16,17] Polymorphic loci have been reported to play a role.[18,19] Martínez-Rodríguez et al[20] reported that rs4291 was associated with an increased risk of hypertension after adjusting for age, gender, BMI, triglyceride, drinking and smoking and with the elevation of ACE enzyme levels. In addition, the function of *ACE* polymorphisms in Alzheimer's Disease cannot be ignored. The study by de Oliveira et al[21] showed that ACE inhibitors, not related to blood pressure, can delay cognitive decline in ACE haplotype carriers with rs1800764-T and rs4291-A. In 2016, they also observed that each A allele of rs4291 resulted in an increase of 3.074 mg/dL urea and 0.044 mg/dl creatinine per year. The use of ACE inhibitors had a protective effect on the change of creatinine, and had no effect on the change of blood pressure.[22] The above research showed that rs4291 carriers with different genotypes had different drug sensitivity.

The *CYP2D6* gene encoded Cytochrome P450 Family 2 Subfamily D Member 6 that catalyses drug metabolism and the synthesis of cholesterol, steroids and other lipids. One report has shown that the gene is highly polymorphic in the population. Lee et al[23] evaluated the association between CYP polymorphisms and the blood concentrations of hydroxychloroquine (HCQ) and its metabolite N-desethyl HCQ (DHCQ) in Korean patients with lupus. They observed that patients with CYP2D6*10 (rs1065852) GG genotype had the highest [DHCQ]/[HCQ] ratio, while patients with AA genotype had the lowest [DHCQ]/[HCQ]

Table 2 Significant Difference SNP and Drug Related Information

Variant	PMID	Molecules	Association	Significant	P-value	#Of Case	#Of Control	Study Size	Bipgeographical Group	Paper Discusses	Gene	More Details
rs4291	27,262,302	Sertraline	Genotype TT is not associated with response to sertraline in people with Depressive Disorder.	No	0.803	55	71	126	Near Eastern	Efficacy	ACE	As compared to fluoxetine. Patients with major depressive disorder were randomized to receive sertraline or fluoxetine. Depression severity determined w/ the 21-item Hamilton Rating Scale for Depression (HAMD-21) before and after the treatment. Response calculated based on 50% reduction in the reported scores. Given allele frequencies were compared between treatment groups in the responsive patients only.
rs4291	27,546,928	Captopril	Genotype AA is associated with decreased severity of Kidney Failure when treated with captopril in people with Alzheimer Disease as compared to genotypes AT + TT.	Yes	0.029	190		190	Unknown	Efficacy	ACE	The A allele conferred a protective effect of creatinine increases over 1 year. Association with the effects on creatinine also found in conjunction with the rs1800764CT genotype.
rs4291	18,727,619	Aspirin	Genotypes AT + TT are associated with increased risk of aspirin intolerance when exposed to aspirin in people with Asthma as compared to genotype AA.	Yes	0.015	81	231	312	East Asian	Toxicity	ACE	
rs4291	20,577,119	Amlodipinechlorthalidonelisinopril	Genotypes AA + AT are associated with decreased fasting glucose when treated with amlodipine, chlorthalidone or lisinopril in people with Hypertension as compared to genotype TT.	Yes	0.0014	9309		9309	Mixed Population	Other	ACE	

(Continued)

Table 2 (Continued).

Variant	PMID	Molecules	Association	Singnificant	P-value	#Of Case	#Of Control	Study Size	Bipgeographical Group	Paper Discusses	Gene	More Details
rs1065852	10,223,777	Alpha-hydroxymetoprolol	Allele A is associated with decreased clearance of alpha-hydroxymetoprolol in healthy individuals as compared to allele G.	Yes	< 0.05	40		40	East Asian	Metabolism/PK	CYP2D6	Alleles complemented to plus strand, relationship described for T188 (P345). As measured by urinary metabolite concentrations.
rs1065852	24,528,284	Citalopramescitalopram	Allele A is associated with plasma concentration of S-didesmethyl-citalopram when treated with citalopram or escitalopram in people with Depressive Disorder, Major as compared to allele G.	Yes	2E-16	435		435	European	Other	CYP2D6	Direction of the association was not given, p = 2.0E-16
rs1065852	23,277,250	Iloperidone	Genotype GG is associated with increased QTc interval when treated with iloperidone in people with Schizophrenia as compared to genotypes AA + AG.	Yes	0.028	128		128	Unknown	Other	CYP2D6	The baseline QTc interval was calculated by averaging the results of 3 electrocardiogram (ECG) measurements per day over 3 consecutive days leading up to iloperidone treatment initiation. The QTc interval at maximum iloperidone blood concentration (Tmax) was calculated by averaging 3 ECG measurements per day (taken 2, 3 and 4 hours after iloperidone was administered) over the last 3 consecutive days of the iloperidone treatment period. From these two averaged measurements, the least squares mean (LSM) change in QTc interval was calculated for each genotype. Patients with the GG genotype had a significantly higher LSM change from baseline, and therefore a greater increase in QTc interval after iloperidone administration, compared to those with the AA or AG genotypes. Please note alleles have been complemented to the positive chromosomal strand.

| rs1051298 | 19,841,321 | Bevacizumabpemetrexed | Allele G is associated with increased progression-free survival when treated with bevacizumab and pemetrexed in people with Lung Neoplasms as compared to allele A. | Yes | 0.01 | 48 | 48 | European | Efficacy | SLC19A1 | This clinical trial evaluated the efficacy and toxicity of pemetrexed combined with bevacizumab as second-line therapy for patients with advanced non-small-cell lung cancer (NSCLC) and to correlate allelic variants in pemetrexed-metabolizing genes with clinical outcome. Patients with previously treated NSCLC received pemetrexed (500 mg/m2 intravenous) combined with bevacizumab (15 mg/kg intravenous) every 3 weeks. The primary end point, evaluated using a one-stage Fleming design for detecting a true success rate of at least 70%, was the proportion of patients who were progression free and on treatment at 3 months. Polymorphisms in genes responsible for pemetrexed transport (reduced folate carrier [SLC19A1]) and metabolism (folylpolyglutamate synthase [FPGS] and gamma-glutamyl hydrolase [GGH]) evaluated in germline DNA (blood) were correlated with treatment outcome. The primary end point for this study was 3-month PFS, and only patients with the SLC19A1 exon 6 (2522)C3T polymorphism showed a significant association with that end point. (GG vs AG vs AA: 57% v29%v 78%, respectively; Fisher's exact test, P = 0.01). Please note that alleles have been complemented to the plus chromosomal strand. |

(Continued)

Table 2 (Continued).

Variant	PMID	Molecules	Association	Singnificant	P-value	#Of Case	#Of Control	Study Size	Bipgeographical Group	Paper Discusses	Gene	More Details
rs1051298	24,732,178	Pemetrexed	Genotypes AA + AG is associated with decreased overall survival when treated with pemetrexed in people with Carcinoma, Non-Small-Cell Lung and Mesothelioma as compared to genotype GG.	Yes	0.016	136		136	Mixed Population	Efficacy	SLC19A1	Advanced stage non-small-cell lung cancer (n=94), malignant mesothelioma (n=42). No association with progression-free survival was seen. Please note alleles have been complemented to the plus chromosomal strand.
rs750155	23,670,235	ABT-751	Allele T is not associated with ABT-751 pharmacokinetic parameters when treated with ABT-751 in people with Neoplasms as compared to allele C.	No		47		47	Mixed Population	Metabolism/ PK	SULT1A1	p-value>0.05
rs750155	15,970,794		Allele T is associated with increased activity of SULT1A1 platelets.	Not stated							SULT1A1	In Caucasians but decreased activity in African Americans.
rs1131596	28,525,903	Methotrexate	Allele G is not associated with response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.	No	> 0.05	317		317	East Asian	Efficacy	SLC19A1	Please note: alleles have been complemented to the + chromosomal strand.
rs1131596	17,404,734	Methotrexate	Allele G is not associated with response to methotrexate in people with Arthritis, Rheumatoid.	Not stated		106		106	Unknown		SLC19A1	This variant alone is insufficient to predict patient response to MTX therapy.

rs1131596	28,525,903	Methotrexate	Genotypes AG + GG are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.	No	0.219	317		317	East Asian	Metabolism/PK	SLC19A1	There is no association between selected SNPs and methotrexate plasma level at 48 h between the first dose of methotrexate infusion. med. MTX concentration: AG+GG 0.41 (0.09–34.05)) vs AA (0.6 (0.14–41.63)). Please note: alleles have been complemented to the + chromosomal strand.
rs1131596	17,404,734		Allele G is associated with decreased expression of SLC19A1.	Not stated							SLC19A1	
rs1131596	28,525,903	Methotrexate	Genotypes AG + GG are not associated with risk of mucositis when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.	No	0.671	317		317	East Asian	Toxicity	SLC19A1	Mucositis refers to grade 3–4 oral mucositis. Please note: alleles have been complemented to the + chromosomal strand.

ratio. This study suggested that [DHCQ]/[HCQ] ratio was associated with *CYP2D6* rs1065852 polymorphism in lupus patients receiving oral HCQ. The CYP polymorphism may explain why the HCQ concentration in blood varies greatly. The effect of individual CYP polymorphisms should be considered in oral HCQ. Recently, López-García et al[24] found single nucleotide polymorphisms associated with pharmacogenomics include CYP2D6*4 (rs1065852), which may affect the efficacy of antiepileptic drugs. Dlouhá et al reported no significant difference in the genotype/allelic frequencies of CYP2D6 (rs1065852) in Roma/Gypsy and Czech (non-Roma) populations.[25] However, Zhang et al observed the frequency of *CYP2D6* rs1065852 in the Lisu population different from the other populations.[26] In our study, rs1065852-A frequency was the highest in the South East Asian populations. Therefore, to evaluate the effect of *CYP2D6* (rs1065852) on drug metabolism, we should not ignore the ethnic factors, especially in the Asian populations.

The membrane protein Folate carrier protein 1 is involved in the regulation of intracellular folate concentration, and is encoded by *SLC19A1* (Solute Carrier Family 19 Member 1) gene.[27] The mutant allele of *SLC19A1* −43T>C was reported to be associated with low folate levels.[28] At present, the treatment response to pemetrexed has been proven to be individual specific. Zhang et al investigated the genetic characteristics of pemetrexed response in 203 Han patients with advanced non-small cell lung cancer (NSCLC).[29] The participants who received pemetrexed alone, the SNP rs1051298 of *SLC19A1* gene increased the risk of all adverse reactions in different cycles of the treatment. Therefore, rs1051298 may be a marker associated with adverse reactions and efficacy of pemetrexed related therapy in Chinese Han patients. In addition, some researchers have found that rs1051296 was also related to drug reactions. Wang et al explored the influence of the miRNA binding site polymorphism (rs1051296) in *SLC19A1* on the serum methotrexate (MTX) concentration in children with acute lymphoblastic leukaemia (ALL) after receiving MTX treatment.[30] In comparison with the GT and TT carriers, the MTX concentration in GG carriers was higher than the treatment threshold. Compared with GT and TT carriers, the delayed elimination of MTX was observed in the GG carriers. Rs1051296 G>T correlated with the MTX plasma concentration. In the research, the frequency of rs1051296 in Tibetans differed from that in the super-populations,

leading to different genotypes of carriers such as MTX, for some drug efficacy.

The results will improve the pharmacogenomic information of the Tibetan population, and deepen the study on the differences in some genetic polymorphisms between the Tibetan population and the other 26 populations in the world. Some limitations of this study are: a small sample size and lack of experiment verification. Further studies are required on the drug efficacy of drug-related gene polymorphism loci in the Tibetan patients, especially for significant loci.

Conclusions

In conclusion, *ACE* rs4291, *SLC19A1* rs1051296 and *CYP2D6* rs1065852 were significant in Tibetans compared to the other 26 nationalities. This study supplemented the knowledge of Tibetan pharmacology, and also showed the relationship between the SNPs with significant differences and drugs more perfectly, thus making the clinical medication safer and personalized for the Tibetan population.

Data Sharing Statement

The datasets used or analysed during the current study are available from the corresponding author upon reasonable request.

Ethical Approval and Consent to Participate

This study was performed in accordance with the World Medical Association Declaration of Helsinki and was approved by the Ethics Committee of the Affiliated Hospital of Xizang Minzu University. Written informed consent was obtained from all of the subjects before participation.

Consent for Publication

The authors have declared that they agreed to publish.

Autonomous Region (2015XZ01G23), the Talent Development Supporting Project entitled Tibet-Shaanxi Himalaya of Xizang Minzu University (2020 Plateau Scholar), and Natural Science Foundation of Tibet Autonomous Region (2015ZR-13-19).

Disclosure

The authors report no conflicts of interest in this work.

References

1. Ma Q, Lu AY. Pharmacogenetics, pharmacogenomics, and individualized medicine. *Pharmacol Rev*. 2011;63(2):437–459. doi:10.1124/pr.110.003533

2. Wang L, Aikemu A, Yibulayin A, et al. Genetic polymorphisms of pharmacogenomic VIP variants in the Uygur population from northwestern China. *BMC Genet*. 2015;16(1):66. doi:10.1186/s12863-015-0232-x

3. Relling MV, Evans WE. Pharmacogenomics in the clinic. *Nature*. 2015;526(7573):343–350. doi:10.1038/nature15817

4. Jin T, Zhao R, Shi X, et al. Genetic polymorphisms study of pharmacogenomic VIP variants in Han ethnic of China's Shaanxi province. *Environ Toxicol Pharmacol*. 2016;46:27–35. doi:10.1016/j.etap.2016.06.026

5. Evans WE, McLeod HL. Pharmacogenomics–drug disposition, drug targets, and side effects. *N Engl J Med*. 2003;348(6):538–549. doi:10.1056/NEJMra020526

6. Cheng Y, Dai R, Chen W, Li Q, Zhang C, Yang T. Genetic polymorphisms of pharmacogenomic VIP variants in the Dai population from Yunnan province. *Mol Genet Genomic Med*. 2020;8(7):e1231. doi:10.1002/mgg3.1231

7. Wang J, Chen Q, Wang L, et al. Identifying novel mutations of NKX2-5 congenital heart disease patients of Chinese minority groups. *Int J Cardiol*. 2011;148(1):102–104. doi:10.1016/j.ijcard.2010.05.041

8. Yi X, Liang Y, Huerta-Sanchez E, et al. Sequencing of 50 human exomes reveals adaptation to high altitude. *Science*. 2010;329(5987):75–78. doi:10.1126/science.1190371

9. Gabriel S, Ziaugra L, Tabbaa D. SNP genotyping using the Sequenom MassARRAY iPLEX platform. *Curr Protocol Hum Gene*. 2009;60(1):12. doi:10.1002/0471142905.hg0212s60

10. He Y, Yang H, Geng T, et al. Genetic polymorphisms of pharmacogenomic VIP variants in the lhoba population of southwest China. *Int J Clin Exp Pathol*. 2015;8(10):13293–13303.

11. Jin T, Yang H, Zhang J, et al. Polymorphisms and phenotypic analysis of cytochrome P450 3A4 in the Uygur population in northwest China. *Int J Clin Exp Pathol*. 2015;8(6):7083–7091.

12. Richard A. Gibbs, John W Belmont, Paul Hardenbol, et al. The International HapMap Project. *Nature*. 2003;426(6968):789–796. doi:10.1038/nature02168

13. Song MK, Lin FC, Ward SE, Fine JP. Composite variables: when and how. *Nurs Res*. 2013;62(1):45–49. doi:10.1097/NNR.0b013e3182741948

14. Burrell LM, Harrap SB, Velkoska E, Patel SK. The ACE2 gene: its potential as a functional candidate for cardiovascular disease. *Clin Sci*. 2013;124(2):65–76. doi:10.1042/cs20120269

15. Probstfield JL, O'Brien KD. Progression of cardiovascular damage: the role of renin-angiotensin system blockade. *Am J Cardiol*. 2010;105(1Suppl):10a–20a. doi:10.1016/j.amjcard.2009.10.006

16. Jiang F, Yang J, Zhang Y, et al. Angiotensin-converting enzyme 2 and angiotensin 1–7: novel therapeutic targets. *Nat Rev Cardiol*. 2014;11(7):413–426. doi:10.1038/nrcardio.2014.59

17. Magrone T, Magrone M, Jirillo E. Focus on receptors for coronaviruses with special reference to angiotensin- Converting enzyme 2 as a potential drug target - A perspective. *Endocr Metab Immune Disord Drug Targets*. 2020;20(6):807–811. doi:10.2174/1871530320666200427112902

18. Zhang Q, Cong M, Wang N, et al. Association of angiotensin-converting enzyme 2 gene polymorphism and enzymatic activity with essential hypertension in different gender: a case-control study. *Medicine*. 2018;97(42):e12917. doi:10.1097/md.0000000000012917

19. Fan Z, Wu G, Yue M, et al. Hypertension and hypertensive left ventricular hypertrophy are associated with ACE2 genetic polymorphism. *Life Sci*. 2019;225:39–45. doi:10.1016/j.lfs.2019.03.059

20. Martínez-Rodríguez N, Posadas-Romero C, Villarreal-Molina T, et al. Single nucleotide polymorphisms of the angiotensin-converting enzyme (ACE) gene are associated with essential hypertension and increased ACE enzyme levels in Mexican individuals. *PLoS One*. 2013;8(5):e65700. doi:10.1371/journal.pone.0065700

21. de Oliveira FF, Chen ES, Smith MC, Bertolucci PHF. Pharmacogenetics of angiotensin-converting enzyme inhibitors in patients with Alzheimer's disease dementia. *Curr Alzheimer Res*. 2018;15(4):386–398. doi:10.2174/1567205014666171016101816

22. Ferreira de Oliveira F, Berretta JM, Suchi CE, Cardoso SM, Ferreira BPH. Pharmacogenetic effects of angiotensin-converting enzyme inhibitors over age-related urea and creatinine variations in patients with dementia due to Alzheimer disease. *Colomb Med*. 2016;47(2):76–80. doi:10.25100/cm.v47i2.2188

23. Lee JY, Vinayagamoorthy N, Han K, et al. Association of polymorphisms of cytochrome P450 2D6 with blood hydroxychloroquine levels in patients with systemic lupus erythematosus. *Arthritis Rheumatol*. 2016;68(1):184–190. doi:10.1002/art.39402

24. López-García MA, Feria-Romero IA, Serrano H, et al. Influence of genetic variants of CYP2D6, CYP2C9, CYP2C19 and CYP3A4 on antiepileptic drug metabolism in pediatric patients with refractory epilepsy. *Pharmacol Rep*. 2017;69(3):504–511. doi:10.1016/j.pharep.2017.01.007

25. Dlouhá L, Adámková V, Šedová L, Olišarová V, Hubáček JA, Tóthová V. Five genetic polymorphisms of cytochrome P450 enzymes in the Czech non-Roma and Czech Roma population samples. *Drug Metab Pers Ther*. 2020. doi:10.1515/dmdi-2020-0103

26. Zhang C, Jiang X, Chen W, et al. Population genetic difference of pharmacogenomic VIP gene variants in the Lisu population from Yunnan Province. *Medicine*. 2018;97(52):e13674. doi:10.1097/md.0000000000013674

27. Yee SW, Gong L, Badagnani I, Giacomini KM, Klein TE, Altman RB. SLC19A1 pharmacogenomics summary. *Pharmacogenet Genomics*. 2010;20(11):708–715. doi:10.107/FPC.0b013e32833eca92

28. Chatzikyriakidou A, Vakalis KV, Kolaitis N, et al. Distinct association of SLC19A1 polymorphism −43T>C with red cell folate levels and of MTHFR polymorphism 677C>T with plasma folate levels. *Clin Biochem*. 2008;41(3):174–176. doi:10.1016/j.clinbiochem.2007.11.006

29. Zhang X, Zhang D, Huang L, et al. Discovery of novel biomarkers of therapeutic responses in han chinese pemetrexed-based treated advanced NSCLC patients. *Front Pharmacol*. 2019;10:944. doi:10.3389/fphar.2019.00944

30. Wang S-M, Sun L-L, Zeng W-X, Wu W-S, Zhang G-L. Effects of a microRNA binding site polymorphism in SLC19A1 on methotrexate concentrations in Chinese children with acute lymphoblastic leukemia. *Med Oncol*. 2014;31(7):62. doi:10.1007/s12032-014-0062-0